iNtRON Biotechnology CEO Yun Gyeong-won Increases Stake to 2.07% Through Open Market Purchase Alongside Treasury Stock Cancellation

iNtRON Biotechnology's registered executive and CEO Vice President Yun Gyeong-won acquired 38,590 common shares at 2,595 KRW per share on June 8, 2026, increasing his holdings from 600,000 to 638,590 shares.
This change raised his individual ownership percentage from 1.94% to 2.07%, a 0.13 percentage point increase, which also reflects the effect of a treasury stock cancellation that reduced total outstanding shares.
The treasury stock cancellation slightly boosts per-share value, but the scale is minimal relative to total shares, limiting direct impact on stock price.
The CEO's open market purchase signals management confidence in the company's value and may provide short-term positive momentum for the stock.
However, the purchase volume is only 0.12% of total shares outstanding, unlikely to cause significant supply-demand changes, and future additional purchases will be key.
[AI Summary]iNtRON Biotechnology CEO's small-scale share purchase combined with treasury stock cancellation sends a mildly positive signal to minority shareholders, but the financial impact is negligible and unlikely to materially alter the stock price. It can be viewed as part of mid-to-long-term shareholder value enhancement efforts.